At the end of May, the 6th Dermatology Drug Development Summit Europe took place in Berlin. This is one of the premier industry forums dedicated to advancing next generation immunodermatology therapies. As the research team also is aiming to develop treatments for EB patients, a delegation travelled to Berlin. They presented their drug discovery efforts, connected with potential partners for future projects and learned about latest technologies that might accelerate development processes leading to better treatment options for EB patients.
The main topics of the congress were the regulatory breakthroughs reshaping the landscape of dermatology diseases such as atopic dermatitis and hidradenitis suppurativa. However, it was highly acknowledged that underserved rare dermatological diseases such as EB are gaining momentum with the new drug approvals as well.
The growing interest in developing drugs for EB patients was also demonstrated by presence of Dr. Hana Cernecka, PharmD from EB Research Institute at the EB house Austria as well as Dr. Marouan Zarrouk from Debra Research, both presenting the challenges and successes of drug development for rare dermatology indication and how joint collaborations are of key importance.
Dr. Hana Cernecka, Pharm. D., from the EB Research Institute at EB House Austria and Dr. Marouan Zarrouk from Debra Research traveled to Berlin for the sixth Dermatology Drug Development Summit Europe to advocate for drug development for people with EB.© DEBRA Austria